| scholarly article | Q13442814 |
| P50 | author | Barbara Kahn | Q60572402 |
| P2093 | author name string | Timothy E McGraw | |
| P2860 | cites work | Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions | Q33782620 |
| Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence | Q34321390 | ||
| Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. | Q34330155 | ||
| New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications | Q37062723 | ||
| Therapeutic targets to reduce cardiovascular disease in type 2 diabetes | Q37464731 | ||
| Adipose tissue as an endocrine organ | Q57257904 | ||
| P433 | issue | 27 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | (RS)-rosiglitazone | Q424771 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 2667-2669 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Rosiglitazone, PPARγ, and type 2 diabetes | |
| P478 | volume | 363 |
| Q99605407 | A New Co-Crystal of Synthetic Drug Rosiglitazone with Natural Medicine Berberine: Preparation, Crystal Structures, and Dissolution |
| Q92307396 | A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese mice |
| Q38217801 | Amorfrutins: A promising class of natural products that are beneficial to health |
| Q35230678 | Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation |
| Q35688497 | Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor γ-dependent mechanism |
| Q42366433 | Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice. |
| Q47096436 | Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks |
| Q35228184 | Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones |
| Q100490624 | Emerging role of tumor cell plasticity in modifying therapeutic response |
| Q35925797 | G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY. |
| Q35060413 | HOX-7 suppresses body weight gain and adipogenesis-related gene expression in high-fat-diet-induced obese mice |
| Q28488095 | Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins |
| Q27301256 | Interaction between IGFBP7 and insulin: a theoretical and experimental study |
| Q35753031 | Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. |
| Q26829098 | Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects |
| Q43097124 | Protein sets define disease states and predict in vivo effects of drug treatment |
| Q28258639 | Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review |
| Q60911519 | Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway |
| Q35860302 | Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency |
| Q90638915 | The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development |
| Q36001145 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study |
| Q34315432 | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. |
| Q35466765 | Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article |
Search more.